Detalhe da pesquisa
1.
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Future Oncol
; 15(17): 1951-1961, 2019 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-30977385
2.
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial.
Lancet Oncol
; 14(10): 933-42, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-23932548
3.
Phase II study (KAMELEON) of single-agent T-DM1 in patients with HER2-positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma.
Cancer Med
; 12(11): 12071-12083, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37119523
4.
De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial.
J Clin Oncol
; 41(22): 3796-3804, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36809046
5.
Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.
J Natl Cancer Inst
; 114(5): 664-675, 2022 05 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34286340
6.
Immune Markers and Tumor-Related Processes Predict Neoadjuvant Therapy Response in the WSG-ADAPT HER2-Positive/Hormone Receptor-Positive Trial in Early Breast Cancer.
Cancers (Basel)
; 13(19)2021 Sep 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638369
7.
Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Cancer Treat Rev
; 86: 102017, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-32335505